PL178314B1 - Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy - Google Patents

Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy

Info

Publication number
PL178314B1
PL178314B1 PL94311820A PL31182094A PL178314B1 PL 178314 B1 PL178314 B1 PL 178314B1 PL 94311820 A PL94311820 A PL 94311820A PL 31182094 A PL31182094 A PL 31182094A PL 178314 B1 PL178314 B1 PL 178314B1
Authority
PL
Poland
Prior art keywords
salts
halogen atom
hydrogen atom
alkyl group
halogen
Prior art date
Application number
PL94311820A
Other languages
English (en)
Polish (pl)
Other versions
PL311820A1 (en
Inventor
Hermann Amschler
Dieter Flockerzi
Beate Gutterer
Armin Hatzelmann
Christian Schudt
Rolf Beume
Ulrich Kilian
Horst Wolf
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4223466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL178314(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of PL311820A1 publication Critical patent/PL311820A1/xx
Publication of PL178314B1 publication Critical patent/PL178314B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL94311820A 1993-07-02 1994-07-02 Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy PL178314B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH199693 1993-07-02
PCT/EP1994/002169 WO1995001338A1 (de) 1993-07-02 1994-07-02 Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren

Publications (2)

Publication Number Publication Date
PL311820A1 PL311820A1 (en) 1996-03-18
PL178314B1 true PL178314B1 (pl) 2000-04-28

Family

ID=4223466

Family Applications (1)

Application Number Title Priority Date Filing Date
PL94311820A PL178314B1 (pl) 1993-07-02 1994-07-02 Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy

Country Status (27)

Country Link
US (1) US5712298A (member.php)
EP (1) EP0706513B1 (member.php)
JP (1) JP3093271B2 (member.php)
KR (1) KR100331255B1 (member.php)
CN (1) CN1046939C (member.php)
AT (1) ATE217612T1 (member.php)
AU (1) AU687087B2 (member.php)
CA (1) CA2165192C (member.php)
CY (2) CY2389B1 (member.php)
CZ (1) CZ290266B6 (member.php)
DE (2) DE59410119D1 (member.php)
DK (1) DK0706513T3 (member.php)
ES (1) ES2176252T3 (member.php)
FI (1) FI112864B (member.php)
FR (1) FR10C0052I2 (member.php)
HU (1) HU220041B (member.php)
LU (1) LU91709I2 (member.php)
LV (1) LV13074B (member.php)
NO (2) NO305598B1 (member.php)
NZ (1) NZ271316A (member.php)
PL (1) PL178314B1 (member.php)
PT (1) PT706513E (member.php)
RU (1) RU2137754C1 (member.php)
SG (1) SG143011A1 (member.php)
SI (1) SI0706513T1 (member.php)
SK (1) SK283263B6 (member.php)
WO (1) WO1995001338A1 (member.php)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US6096768A (en) * 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
PT923568E (pt) * 1996-08-19 2003-04-30 Altana Pharma Ag Novas benzofuran-4-carboxamidas
JP2001504457A (ja) * 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
CN1123345C (zh) * 1997-02-17 2003-10-08 奥坦纳医药公司 治疗ards或irds的组合物
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6172118B1 (en) * 1998-04-14 2001-01-09 Smithkline Beecham Corporation Compounds
WO2000053182A2 (en) * 1999-03-10 2000-09-14 Byk Gulden Lomberg Chemische Fabrik Gmbh 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US6498173B1 (en) 1999-05-04 2002-12-24 Altana Pharma Ag Synergistic combination comprising roflumilast and a pde-3 inhibitor
AU777012B2 (en) * 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
EP1289961A1 (en) 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
DE10043074A1 (de) 2000-09-01 2002-03-14 Aventis Cropscience Gmbh Herbizid wirksame Benzoylcyclohexandione
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
ES2247325T3 (es) 2001-05-24 2006-03-01 MERCK FROSST CANADA & CO. Inhibidores de 1-biaril-1,8-naftiridin-4-ona fosfodiesterasa-4.
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
DE10207160A1 (de) * 2002-02-20 2003-12-18 Altana Pharma Ag Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
RU2227797C2 (ru) * 2002-03-29 2004-04-27 Пермская государственная фармацевтическая академия 4-метил-2-пиридиламид тетрахлорфталевой кислоты, проявляющий гипертензивную активность
PL373000A1 (en) * 2002-05-07 2005-08-08 Altana Pharma Ag Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
EP1506016A2 (en) * 2002-05-07 2005-02-16 ALTANA Pharma AG New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
CA2484654A1 (en) * 2002-05-16 2003-11-27 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
CA2486910C (en) * 2002-05-28 2011-11-29 Altana Pharma Ag Ophthalmological use of roflumilast for the treatment of diseases of the eye
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
CN1688545A (zh) 2002-07-19 2005-10-26 记忆药物公司 磷酸二酯酶4抑制剂,包括n－取代的苯胺及二苯胺类似物
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
AU2003288901A1 (en) * 2002-09-06 2004-03-29 Merck And Co., Inc. Treatment of rheumatoid arthritis by inhibition of pde4
CN1684738A (zh) 2002-09-20 2005-10-19 爱尔康公司 细胞因子合成抑制剂用于治疗干眼病的用途
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
PL376769A1 (pl) 2002-10-23 2006-01-09 Glenmark Pharmaceuticals Ltd. Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
MXPA05005345A (es) * 2002-11-19 2005-08-26 Memory Pharm Corp Inhibidores de fosfodiesterasa 4.
CA2506962C (en) * 2002-11-27 2012-01-03 Altana Pharma Ag Synergistic combination comprising roflumilast and formoterol
TW200426138A (en) * 2002-12-10 2004-12-01 Hoffmann La Roche Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004087211A2 (en) 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
GEP20084526B (en) 2003-04-11 2008-11-10 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
WO2004098598A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098595A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098597A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
UA83041C2 (ru) 2003-05-22 2008-06-10 Нікомед Гмбх Композиция, которая включает ингибитор pde4 и ингибитор pde5
KR20060021870A (ko) * 2003-05-30 2006-03-08 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의용도
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
AU2004269923B2 (en) * 2003-09-05 2010-05-13 Takeda Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
EP1670742A1 (en) * 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
WO2005046676A1 (en) * 2003-11-12 2005-05-26 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
WO2005049087A1 (ja) 2003-11-20 2005-06-02 Astellas Pharma Inc. 慢性骨盤痛症候群治療剤
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ES2381116T3 (es) * 2004-02-06 2012-05-23 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos e inhibidores de fosfodiesterasa tipo 4 para el tratamiento de enfermedades respiratorias
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
WO2005077906A1 (en) 2004-02-18 2005-08-25 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
US20070167496A1 (en) * 2004-02-27 2007-07-19 Attana Pharma Ag Roflumilast and glycopyrronium combination
WO2005085225A1 (en) 2004-03-03 2005-09-15 Altana Pharma Ag Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors
EP1775283A4 (en) * 2004-07-14 2008-12-10 Japan Tobacco Inc 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
BRPI0513286A (pt) 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
DE102004046236A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US20080085858A1 (en) * 2004-10-13 2008-04-10 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical Composition
JPWO2006041121A1 (ja) * 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および／または予防剤
BRPI0516341A (pt) 2004-10-13 2008-09-02 Glenmark Pharmaceuticals Sa método para preparação de intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, método para a preparação de compostos intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzeno [b,d] furano-1-carboxamida, método para a sìntese de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida e seu sal sódico de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
DK1831227T3 (da) 2004-12-17 2013-08-19 Glenmark Pharmaceuticals Sa Hidtil ukendte, heterocykliske forbindelser, der er anvendelige til behandling af inflammatoriske og allergiske forstyrrelser
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
CN101137368B (zh) * 2005-03-08 2012-05-16 奈科明有限责任公司 治疗糖尿病的罗氟司特
RU2420285C2 (ru) * 2005-03-16 2011-06-10 Меда Фарма Гмбх Унд Ко.Кг Комбинация r,r-гликопирролата и монтелукаста для лечения респираторных заболеваний и фармацевтическая композиция на ее основе
BRPI0610498A2 (pt) 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
MX2007013766A (es) * 2005-05-11 2008-01-28 Nycomed Gmbh Combinacion de inhibidor pde4 de roflumilast y un derivado de tetrahidrobiopterina.
US20090209599A1 (en) * 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006306240A1 (en) * 2005-10-24 2007-05-03 Novartis Ag Combination of histone deacetylase inhibitors and radiation
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
DK2098248T3 (da) * 2005-12-21 2012-09-17 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika, glucocorticoider og beta2-agonister til behandling af inflammatoriske sygdomme
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2378281T3 (es) 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
EP2049102A4 (en) * 2006-07-14 2010-12-22 Ranbaxy Lab Ltd POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
EP2058310A4 (en) 2006-09-01 2010-11-17 Kyorin Seiyaku Kk PYRAZOLOPYRIDINCARBOXYL ACID AMID DERIVATIVE AND THE DERIVATIVELY PHOSPHODIESTERASE (PDE) INHIBITOR
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036678A2 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20080221103A1 (en) * 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
KR100844125B1 (ko) * 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
WO2008138939A1 (en) 2007-05-16 2008-11-20 Nycomed Gmbh Pyrazolone derivatives as pde4 inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
CA2711865A1 (en) 2008-01-11 2009-07-16 Astellas Pharma Inc. A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency
BRPI0912029A2 (pt) 2008-02-01 2020-06-30 Orchid Research Laboratories Limited novos heterociclos
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ603136A (en) 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
CN102958937B (zh) 2010-06-24 2016-03-30 利奥制药有限公司 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物
CN102311382B (zh) * 2010-06-29 2014-05-21 大道隆达（北京）医药科技发展有限公司 罗氟司特的晶态及其制备方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102093194B (zh) * 2010-12-24 2014-01-08 江苏先声药物研究有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
CN102690194B (zh) * 2011-03-24 2014-06-25 上海通远生物科技有限公司 3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN102276522B (zh) * 2011-06-15 2013-04-17 无锡泓兴生物医药科技有限公司 一种制备罗氟司特的方法及其中间体
CN102336703B (zh) * 2011-07-20 2013-09-25 华润赛科药业有限责任公司 一种制备罗氟司特的方法
CN102351787B (zh) * 2011-08-18 2014-08-13 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特化合物
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
CN102336704B (zh) * 2011-10-19 2013-04-17 丁克 一种制备罗氟司特的方法
WO2013057013A2 (en) * 2011-10-21 2013-04-25 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN102336705B (zh) * 2011-10-28 2013-03-27 成都苑东药业有限公司 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
CA2855021A1 (en) * 2011-11-09 2013-05-23 Mylan Laboratories Ltd Process for the preparation of roflumilast
WO2013081565A1 (en) 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
WO2013077830A1 (en) 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
WO2013084182A1 (en) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
CN102603623A (zh) * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013131255A1 (en) 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103630613B (zh) * 2012-08-21 2015-08-05 北大方正集团有限公司 分离并检测罗氟司特及其中间体的方法
WO2014060464A1 (en) 2012-10-17 2014-04-24 Interquim, S.A. Process for preparing roflumilast
KR102154104B1 (ko) 2013-01-28 2020-09-09 인코젠 쎄라퓨틱스 프라이빗 리미티드 로플루밀라스트 n- 옥사이드의 흡입에 의한 자가면역, 호흡 및 염증성 장애의 치료방법
CA2899963A1 (en) 2013-02-04 2014-08-07 Grunenthal Gmbh Novel substituted condensed pyrimidine compounds
WO2014117947A1 (en) 2013-02-04 2014-08-07 Grünenthal GmbH 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
HK1220696A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 鸟苷酸环化酶激动剂及其用途
TW201512189A (zh) 2013-04-16 2015-04-01 Gruenenthal Chemie 新型被取代之嘧啶縮合化合物
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
CN103304475A (zh) * 2013-06-13 2013-09-18 湖南千金湘江药业股份有限公司 苯甲酰胺化合物及其制备方法和用途
EP3030565B1 (en) 2013-08-09 2017-07-19 Grünenthal GmbH Novel substituted condensed pyrimidine compounds
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
AU2015260841A1 (en) 2014-05-12 2016-12-01 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
AR101198A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas como inhibidores de pde4b
AR101196A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Compuestos de pirimidina sustituidos
AR101197A1 (es) 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas
CN104130116B (zh) * 2014-08-18 2015-11-11 朱丽平 一种制备罗氟司特中间体的方法
JP5938537B1 (ja) 2014-10-24 2016-06-22 久光製薬株式会社 プロドラッグ
CN104447245B (zh) * 2014-10-29 2017-06-06 成都森科制药有限公司 罗氟司特中间体、中间体制备方法及罗氟司特的制备方法
KR20170034707A (ko) 2015-09-21 2017-03-29 한미약품 주식회사 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN105523954B (zh) * 2016-02-05 2017-07-18 徐江平 3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
BR112020003973A2 (pt) 2017-10-23 2020-09-01 Boehringer Ingelheim International Gmbh combinação de agentes ativos para o tratamento de doenças pulmonares intersticiais fibrosantes progressivas (pf-ild)
US12042558B2 (en) 2018-06-04 2024-07-23 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CA3166300A1 (en) 2020-01-31 2021-08-05 David W. Osborne Topical roflumilast formulation having improved delivery and plasma half-life
EP4140480A4 (en) 2020-04-23 2024-06-12 Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. DRUG COMBINATION AND USE
CN111777550A (zh) * 2020-06-01 2020-10-16 山东希尔康泰药业有限公司 罗氟司特结晶性粉末原料药生产制备方法
EP4255393B1 (en) 2020-12-04 2025-05-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN116963773A (zh) * 2021-01-21 2023-10-27 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
EP4456870A1 (en) 2021-12-28 2024-11-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
EP4456877A1 (en) 2021-12-28 2024-11-06 Arcutis Biotherapeutics, Inc. Topical aerosol foams
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
WO2025054483A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions
WO2025265054A2 (en) 2024-06-21 2025-12-26 Arcutis Biotherapeutics, Inc. Methods of treatment using topical roflumilast compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308239A1 (de) * 1983-03-09 1984-09-13 Basf Ag, 6700 Ludwigshafen N-acyl-anthranilsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
JPS62158253A (ja) * 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
SU1512053A1 (ru) * 1988-01-29 1991-01-15 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 2-Окси-3,5-дигалоид-N-[3-хлор-4-(4-галоиднафтокси-1)-фенил]-бензамиды, обладающие активностью при экспериментальном описторхозе и гименолепидозе
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
WO1992019602A1 (de) * 1991-04-26 1992-11-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridazine
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
DE69309030T2 (de) * 1992-06-15 1997-09-25 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
MX9304571A (es) * 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8604064B2 (en) 2003-03-10 2013-12-10 Takeda Gmbh Process for the preparation of roflumilast
US8618142B2 (en) 2003-03-10 2013-12-31 Takeda Gmbh Process for the preparation of roflumilast
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast

Also Published As

Publication number Publication date
ATE217612T1 (de) 2002-06-15
CZ196A3 (en) 1996-06-12
LV13074B (en) 2004-03-20
ES2176252T3 (es) 2002-12-01
JPH08512041A (ja) 1996-12-17
CA2165192A1 (en) 1995-01-12
AU7490794A (en) 1995-01-24
CA2165192C (en) 2001-04-24
NO955211L (no) 1995-12-21
NZ271316A (en) 1997-11-24
KR960703400A (ko) 1996-08-17
RU2137754C1 (ru) 1999-09-20
SK161795A3 (en) 1996-07-03
CZ290266B6 (cs) 2002-06-12
WO1995001338A1 (de) 1995-01-12
DE122010000043I1 (de) 2011-01-27
HUT73232A (en) 1996-07-29
SK283263B6 (sk) 2003-04-01
PL311820A1 (en) 1996-03-18
HU220041B (hu) 2001-10-28
CY2010015I1 (el) 2011-02-02
NO305598B1 (no) 1999-06-28
CY2389B1 (en) 2004-09-10
FI956333A0 (fi) 1995-12-29
CN1126468A (zh) 1996-07-10
KR100331255B1 (ko) 2002-10-25
CY2010015I2 (el) 2011-02-02
FR10C0052I2 (member.php) 2011-11-25
LU91709I2 (fr) 2010-09-21
PT706513E (pt) 2002-10-31
CN1046939C (zh) 1999-12-01
SI0706513T1 (en) 2002-10-31
FI956333A7 (fi) 1995-12-29
EP0706513B1 (de) 2002-05-15
JP3093271B2 (ja) 2000-10-03
SG143011A1 (en) 2008-06-27
FI112864B (fi) 2004-01-30
NO955211D0 (no) 1995-12-21
AU687087B2 (en) 1998-02-19
DK0706513T3 (da) 2002-09-09
US5712298A (en) 1998-01-27
NO2010018I1 (no) 2010-10-18
NO2010018I2 (member.php) 2011-10-17
DE59410119D1 (de) 2002-06-20
EP0706513A1 (de) 1996-04-17
FR10C0052I1 (member.php) 2011-01-14
HU9503541D0 (en) 1996-02-28
HK1011690A1 (en) 1999-07-16

Similar Documents

Publication Publication Date Title
PL178314B1 (pl) Benzamidy podstawione grupą fluoroalkoksylową, hamujące fosfodiesterazę cyklicznych nukleotydów, sposób ich otrzymywania i lek zawierający podstawione benzamidy
RU2138498C1 (ru) Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе
US5750545A (en) Triazole derivative and pharmaceutical use thereof
JP3000674B2 (ja) ジヒドロピラゾロピロール類
US5902824A (en) Phenyldihydrobenzofuranes
ES2188983T4 (es) Nuevas benzofuran-4-carboxamidas.
EA001205B1 (ru) Новые фенантридины
CA2335104C (en) Arylalkanoylpyridazines
US6043263A (en) (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
ES2206909T3 (es) Derivados de tetrazol.
JPS6136282A (ja) 窒素を含む複素環式化合物からなる医薬品とその製造方法
JP2002523505A (ja) Ｐｄｅ３−及びｐｄｅ−４抑制作用を有するベンゾナフチリデン−ｎ−オキシド
ES2236288T3 (es) 6-heteroarilfenantridinas.
JP2004526712A (ja) ６−フェニルベンゾナフチリジン
US20110144156A1 (en) A3 adenosine receptor allosteric modulators
US6020340A (en) Imidazopyridines
CA2378595A1 (en) Benzoylpyridazines
PL198759B1 (pl) Pochodne benzimidazolu i/lub benzoksazolu